alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
**Exhibit99.1**

 

## **CERTIFICATION**

 

**The undersigned certify pursuantto 18 U.S.C. § 1350, that:**

 

(1)                                The accompanying Quarterly Report on Form10-QSB for the period ended January 31, 2003 fully complies with the requirements of Section 13(a) or 15(d) of theSecurities Exchange Act of 1934; and

 

(2)                                The information contained in the accompanying Reportfairly presents, in all material respects,the financial condition and results of operations of the Company.

 

 
| Date: March 14, 2003 | /s/ Richard E. Jahnke                  |   |
|----------------------|----------------------------------------|--------|
|                 | President and  Chief Executive Officer |
|                 |                                   |
|                 |                                   |
| Date: March 14, 2003 | /s/ Dale H. Johnson                    |   |
|                 | Chief Financial Officer                |
|                      |                                        |        |  |

 

----
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.5880 Transferrin immunological test system. ( a ) *Identification.* A transferrin immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the transferrin (an iron-binding and transporting serum protein) in serum, plasma, and other body fluids. Measurement of transferrin levels aids in the diagnosis of malnutrition, acute inflammation, infection, and red blood cell disorders, such as iron deficiency anemia.
( b ) *Classification.* Class II (performance standards).
#### § 1.101-5 [Reserved]
[if !vml]>[endif]>
[if !vml]>[endif]>
Youhave reached the Federal Depository Library Program Electronic Collection(FDLP/EC) Archive. This archive assures ongoing access to publications in theFDLP/EC. Access to publications in the archive is available through GPO's suiteof cataloging and locator services, including the Catalog of U.S. GovernmentPublications (CGP).
**Title:****State Community Development Block GrantProgram : guide to national objectives and eligible activities for state CDBGProgram.
 
SuDoc Number:HH 1.6/3:C 73/16
Item Number:0582-E (online)
CGP System Number:001017954
 
[if !vml]>[endif]>
Cover  and Letter 
[if !vml]>[endif]>
Introduction
[if !vml]>[endif]>
Chapter  1 SELECTING ACTIVITIES THAT COMPLY 
[if !vml]>[endif]>
Chapter  2 CATEGORIES OF ELIGIBLE ACTIVITIES 
[if !vml]>[endif]>
Chapter  3 MEETING A NATIONAL OBJECTIVE 
[if !vml]>[endif]>
Chapter  4 OVERALL EXPENDITURES LEVEL-BENEFIT TO L/M INCOME PERSONS 
[if !vml]>[endif]>
**Appendices**
[if !vml]>[endif]>
Appendix    A: The Housing and Community Development Act of 1974 (HCDA), Title 1,    105(a) 
[if !vml]>[endif]>
Appendix    B: Code of Federal Regulations, Title 24 570.482 - .497 
[if !vml]>[endif]>
Appendix    C: Public Benefit Standards 
[if !vml]>[endif]>
Appendix    D: Special Assessments under the CDBG Program 
[if !vml]>[endif]>
Appendix    E: Community Revitalization Strategy Areas 
[if !vml]>[endif]>
Appendix    F: Making the Most of Your CDBG Resources 
[if !vml]>[endif]>
Appendix    G: One Percent Technical Assistance Set-Aside 
[if !vml]>[endif]>
Appendix    H: Selling or Securitizing CDBG-funded Loans Using the Section 108    Program and Other Secondary Markets 
[if !vml]>[endif]>
Appendix    I: Model Record-Keeping Requirements 
[if !vml]>[endif]>
Appendix    J: Code of Federal Regulations, Entitlement Eligibility, Part 570.200 -    .207 
 
 
** 
**Permanent Public Access
** 
Title 44 of  the United States Code (44 U.S.C. Section 1911) stipulates that public access  to official Government information products disseminated through the Federal  Depository Library Program (FDLP) must be maintained permanently in regional  depository libraries and by depository libraries not served by a regional  library. Since online products are not physically distributed to depository  libraries for retention, GPO has assumed responsibility for the provision of  permanent access to Government information products residing on FDsys  servers.
GPO's  permanent public access commitment is also met by bringing  agency-disseminated Internet resources under the purview of GPO and  incorporating them into a digital archive. GPO captures copies of agency  electronic information products, and creates PURLs so that users will be  automatically redirected to the archived products if the information is no  longer accessible on the agency Web site. Please refer to the report Managing  the FDLP Electronic Collection: A Policy and Planning Document for more  information.
 
August 30, 2017********
Editorial Note on Part 882
Editorial Note: Nomenclature changes to part 882 appear at 73 FR 35341, June 23, 2008.

§ 882.1240 Echoencephalograph. ( a ) *Identification.* An echoencephalograph is an ultrasonic scanning device (including A-scan, B-scan, and doppler systems) that uses noninvasive transducers for measuring intracranial interfaces and blood flow velocity to and in the head.
( b ) *Classification.* Class II (performance standards).
COURT OF APPEALS

	SECOND DISTRICT OF TEXAS

	FORT WORTH

	NO. 2-09-176-CR

ROBERT WYMAN PARR	APPELLANT

	V.

THE STATE OF TEXAS	STATE

	------------

	FROM THE 355TH DISTRICT COURT OF HOOD COUNTY

	------------

	MEMORANDUM OPINION1

	------------

	On August 14, 2007, pursuant to a plea bargain, Appellant Robert Wyman Parr pled guilty to indecency with a child,2 a second-degree felony.  The trial court placed Appellant on ten years’ deferred adjudication community supervision and imposed a $1,500 fine.  Less than fourteen months later, the State filed a motion to adjudicate guilt, alleging that Appellant had violated the terms and conditions of his community supervision in various ways, including by committing a new offense—DWI (Paragraph C) and by failing to abstain from the use of alcohol (Paragraph E).  Appellant pled true to these two paragraphs but not true to the remaining paragraphs.  After the hearing, the trial court found that Appellant had violated the terms and conditions of his community supervision in various ways, including by committing a new offense—DWI and by failing to abstain from the use of alcohol. The trial court adjudicated Appellant’s guilt and sentenced him to twelve years’ confinement. 

	Appellant’s court-appointed appellate counsel has filed a motion to withdraw as counsel and a brief in support of that motion.  In the brief, counsel avers that, in his professional opinion, this appeal is frivolous.  Counsel’s brief and motion meet the requirements of Anders v. California3 by presenting a professional evaluation of the record demonstrating why there are no arguable grounds for relief.4  Appellant has also filed a pro se response to the Anders brief.  The State has not filed a brief. 

	Once an appellant’s court-appointed counsel files a motion to withdraw on the ground that the appeal is frivolous and fulfills the requirements of Anders, we are obligated to undertake an independent examination of the record to see if there is any arguable ground that may be raised on his behalf.5  Only then may we grant counsel’s motion to withdraw.6

	We have carefully reviewed the record, counsel’s brief, and Appellant’s response.  We agree with counsel that the appeal is wholly frivolous and without merit.  We find nothing in the record that might arguably support the appeal.7  Consequently, we grant the motion to withdraw and affirm the trial court’s judgment.

								PER CURIAM

PANEL:  DAUPHINOT, GARDNER, and MEIER, JJ.

DO NOT PUBLISH

Tex. R. App. P. 47.2(b)

DELIVERED:  January 28, 2010
§ 520.2520b Trichlorfon boluses. ( a ) *Specifications.* Each bolus contains either 7.3, 10.9, 14.6, or 18.2 g of trichlorfon.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in horses* — ( 1 ) *Amount.* 18.2 milligrams per pound of body weight, except for strongyles use 36.4 milligrams per pound of body weight.
( 2 ) *Indications for use.* For horses for removal of bots (*Gastrophilus nasalis, Gastrophilus intestinalis*), large strongyles (*Strongylus vulgaris*), small strongyles, large roundworms (ascarids, *Parascaris equorum*), and pinworms (*Oxyuris equi*).
( 3 ) *Limitations.* Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[45 FR 48127, July 18, 1980. Redesignated and amended at 79 FR 28833, May 20, 2014]
Editorial Note on Part 882
Editorial Note: Nomenclature changes to part 882 appear at 73 FR 35341, June 23, 2008.

§ 882.5805 Repetitive transcranial magnetic stimulation system. ( a ) *Identification.* A repetitive transcranial magnetic stimulation system is an external device that delivers transcranial repetitive pulsed magnetic fields of sufficient magnitude to induce neural action potentials in the prefrontal cortex to treat the symptoms of major depressive disorder without inducing seizure in patients who have failed at least one antidepressant medication and are currently not on any antidepressant therapy.
( b ) *Classification.* Class II (special controls). The special control is FDA's “Class II Special Controls Guidance Document: Repetitive Transcranial Magnetic Stimulation System.” See § 882.1(e) for the availability of this guidance document.
[76 FR 44491, July 26, 2011]
Editorial Note on Part 878
Editorial Note: Nomenclature changes to part 878 appear at 73 FR 35341, June 23, 2008.

§ 878.4350 Cryosurgical unit and accessories. ( a ) *Identification* — ( 1 ) *Cryosurgical unit with a liquid nitrogen cooled cryoprobe and accessories.* A cryosurgical unit with a liquid nitrogen cooled cryoprobe and accessories is a device intended to destroy tissue during surgical procedures by applying extreme cold.
( 2 ) *Cryosurgical unit with a nitrous oxide cooled cryoprobe and accessories.* A cryosurgical unit with a nitrous oxide cooled cryoprobe and accessories is a device intended to destroy tissue during surgical procedures, including urological applications, by applying extreme cold.
( 3 ) *Cryosurgical unit with a carbon dioxide cooled cryoprobe or a carbon dioxide dry ice applicator and accessories.* A cryosurgical unit with a carbon dioxide cooled cryoprobe or a carbon dioxide dry ice applicator and accessories is a device intended to destroy tissue during surgical procedures by applying extreme cold. The device is intended to treat disease conditions such as tumors, skin cancers, acne scars, or hemangiomas (benign tumors consisting of newly formed blood vessels) and various benign or malignant gynecological conditions affecting vulvar, vaginal, or cervical tissue. The device is not intended for urological applications.
( b ) *Classification.* Class II.
Amended and Restated Term Note



Exhibit 10.77 
 
AMENDED AND RESTATED TERM NOTE 
 

	 $3,000,000
	  	 	  	 February 3, 2003


 
For
value received, the undersigned, RF MONOLITHICS, INC., a Delaware corporation (the “Borrower”), hereby promises to pay on the Termination Date under the Credit Agreement (defined below), to the order of WELLS FARGO BUSINESS CREDIT, INC., a
Minnesota corporation (the “Lender”), at its main office in Minneapolis, Minnesota, or at any other place designated at any time by the holder hereof, in lawful money of the United States of America and in immediately available funds, the
principal sum of Three Million and No/100 Dollars ($3,000,000), or, if less, the aggregate unpaid principal amount of all amounts advanced under the Original Term Note (as defined herein), together with interest on the principal amount hereunder
remaining unpaid from time to time, computed on the basis of the actual number of days elapsed and a 360-day year, from the date hereof until this Note is fully paid at the rate from time to time in effect under the Amended and Restated Credit and
Security Agreement of even date herewith (as the same may hereafter be amended, supplemented or restated from time to time, the “Credit Agreement”) by and between the Lender and the Borrower. The principal hereof and interest accruing
thereon shall be due and payable as provided in the Credit Agreement. This Note may be prepaid only in accordance with the Credit Agreement. 
 
This Note is issued pursuant, and is subject, to the Credit Agreement, which provides, among other things, for acceleration hereof. This
Note is the Term Note referred to in the Credit Agreement. This Note is secured, among other things, pursuant to the Credit Agreement and the Security Documents as therein defined, and may now or hereafter be secured by one or more other security
agreements, mortgages, deeds of trust, assignments or other instruments or agreements. 
 
The Borrower hereby agrees to pay all costs of collection, including attorneys’ fees and legal expenses in the event this Note is not paid when due, whether or not legal proceedings are commenced.

 
Presentment or other demand for payment, notice
of accelerating notice of intent to accelerate, notice of dishonor, accelerate, protest and all other notices of any kind are expressly waived. 
 
This Note is given in amendment, restatement and modification, but not in extinguishment or novation, of the indebtedness evidenced by
that certain Term Note in the principal amount of $3,000,000.00, dated December 8, 2000, executed by the Borrower and payable to the order of the Lender (the “Original Term Note”). 
 

	 RF MONOLITHICS, INC.

	
	 By:
	 	 /s/ David M. Kirk


	 	 	 David M. Kirk
 President
#### § 1.1233-2 Hedging transactions.

The character of gain or loss on a short sale that is (or is identified as being) part of a hedging transaction is determined under the rules of § 1.1221-2.

[T.D. 8555, 59 FR 36367, July 18, 1994]
Editorial Note on Part 880
Editorial Note: Nomenclature changes to part 880 appear at 73 FR 35341, June 23, 2008.

§ 880.6800 Washers for body waste receptacles. ( a ) *Identification.* A washer for body waste receptacles is a device intended for medical purposes that is used to clean and sanitize a body waste receptacle, such as a bedpan. The device consists of a wall-mounted plumbing fixture with a door through which a body waste receptacle is inserted. When the door is closed the body waste receptacle is cleaned by hot water, steam, or germicide.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 880.9. The device also is exempt from the current good manufacturing practice requirements of the quality system regulation in part 820 of this chapter, with the exception of § 820.180, with respect to general requirements concerning records, and § 820.198, with respect to complaint files.
[45 FR 69682, Oct. 21, 1980, as amended at 66 FR 38807, July 25, 2001]
Knox CountyAir Pollution ControlBoard Regulatory Revisions January 21, 2015 

### REDLINE-Sl1U-KEOUT

2. Amend Section 26.5.C so thatitreads as follows: 

### " 

### c. Emissions Statement 1. Owners and operators ofsources with actual emissions greater than 25 tons per year of nitrogen oxides or volatile organic compounds shall provide an annual report as prescribed by the Director.
| (logo) WELLS  FARGO | **Commercial  Mortgage Servicing**D1050-084,  8th Floor  401 South Tryon St.  Charlotte, NC 28202  1-800-326-1334 |
|---------------------|-------------------------------------------------------------------------------------------------------------------|

 

 

 **ANNUAL STATEMENT OFCOMPLIANCE**

 

 

Reference is hereby made to that certain Pooling and ServicingAgreement dated as of August 1, 2015, by and among WELLS FARGO COMMERCIALMORTGAGE SECURITIES, INC., as Depositor, WELLS FARGO BANK, NATIONALASSOCIATION, as General Master Servicer, CWCAPITAL ASSET MANAGEMENT LLC, asGeneral Special Servicer, NATIONAL COOPERATIVE BANK, N.A., as NCB MasterServicer, NATIONAL COOPERATIVE BANK, N.A, as NCB Special Servicer, PENTALPHASURVEILLANCE LLC, as Trust Advisor, WELLS FARGO BANK, NATIONAL ASSOCIATION, asCertificate Administrator, as Tax Administrator and as Custodian and WILMINGTONTRUST, NATIONAL ASSOCIATION, as Trustee, with respect to Commercial MortgagePass-Through Certificates Series 2015-C30 (the "Agreement").Capitalized terms used herein not otherwise defined shall have the meaningsassigned in the Agreement.

 

Pursuant to Section 11.12 of this Agreement, I, Leslie Hayton,Managing Director of Commercial Mortgage Services do hereby certify that:

 

1.      A review of the activities of the General Master Servicer duringthe period from January 1, 2018 through December 31, 2018 (the “ReportingPeriod”), and of its performance per the Agreement during such period has beenmade under my supervision, and

 

2.      To the best of my knowledge, based on such review, the GeneralMaster Servicer, has fulfilled all of its obligations under this Agreement inall material respects throughout the Reporting Period.

 

 

IN WITNESS WHEREOF,the undersigned has executed this Certificate as of the 28th day of February 2019.

 

 

/s/Leslie Hayton

LeslieHayton

ManagingDirector

WellsFargo Bank

 

 

| Wells Fargo Bank,  N.A. | (logo) Together  we’ll go far |
|-------------------------|-------------------------------------|
§ 884.5350 Contraceptive diaphragm and accessories. ( a ) *Identification.* A contraceptive diaphragm is a closely fitting membrane placed between the posterior aspect of the pubic bone and the posterior vaginal fornix. The device covers the cervix completely and is used with a spermicide to prevent pregnancy. This generic type of device may include an introducer.
( b ) *Classification.* Class II (performance standards).
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS  SCHEDULE  CONTAINS  SUMMARY  FINANCIAL   INFORMATION  EXTRACTED  FROM  THE
CONSOLIDATED  BALANCE SHEETS  (UNAUDITED) AS OF MAY 3, 1998 AND NOVEMBER 2, 1997
AND THE CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) FOR THE QUARTERS ENDED
MAY 3, 1998 AND MAY 4, 1997
</LEGEND>
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          NOV-01-1998
<PERIOD-START>                             NOV-03-1997
<PERIOD-END>                               MAY-03-1998
<EXCHANGE-RATE>                                      1
<CASH>                                          35,454
<SECURITIES>                                         0
<RECEIVABLES>                                  281,712
<ALLOWANCES>                                    11,752
<INVENTORY>                                    518,259
<CURRENT-ASSETS>                               839,055
<PP&E>                                         183,915
<DEPRECIATION>                                  91,589
<TOTAL-ASSETS>                               1,054,923
<CURRENT-LIABILITIES>                          763,194
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           196
<OTHER-SE>                                     277,066
<TOTAL-LIABILITY-AND-EQUITY>                 1,054,923
<SALES>                                      1,326,950
<TOTAL-REVENUES>                             1,326,950
<CGS>                                        1,242,369
<TOTAL-COSTS>                                1,242,369
<OTHER-EXPENSES>                                 5,600
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 988
<INCOME-PRETAX>                                (9,842)
<INCOME-TAX>                                   (3,885)
<INCOME-CONTINUING>                            (5,957)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (5,957)
<EPS-PRIMARY>                                   (0.30)
<EPS-DILUTED>                                   (0.30)
        

</TABLE>
Editorial Note on Part 892
Editorial Note: Nomenclature changes to part 892 appear at 73 FR 35341, June 23, 2008.

§ 892.1700 Diagnostic x-ray high voltage generator. ( a ) *Identification.* A diagnostic x-ray high voltage generator is a device that is intended to supply and control the electrical energy applied to a diagnostic x-ray tube for medical purposes. This generic type of device may include a converter that changes alternating current to direct current, filament transformers for the x-ray tube, high voltage switches, electrical protective devices, or other appropriate elements.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 892.9.
[53 FR 1567, Jan. 20, 1988, as amended at 61 FR 1125, Jan. 16, 1996; 66 FR 38819, July 25, 2001]
<Page>

                                                                          [LOGO]

                  CONSENT OF INDEPENDENT ACCOUNTANTS

We hereby consent to the use in this Post-Effective Amendment No. 11 to the
registration statement on Form N-4 (No. 033-63935) (the "Registration
Statement") of our report dated February 13, 2003, relating to the financial
statements of Fortis Benefits Insurance Company, which appears in such
Registration Statement. We also consent to the reference to us under the heading
"Independent Accountants" in such Registration Statement.

PRICEWATERHOUSECOOPERS LLP
Minneapolis, Minnesota
April 7, 2003
Editorial Note on Part 886
Editorial Note: Nomenclature changes to part 886 appear at 73 FR 35341, June 23, 2008.

§ 886.5300 Tear electrostimulation device. ( a ) *Identification.* A tear electrostimulation device is a non-implantable, electrostimulation device intended to increase tear production.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) Non-clinical performance testing must assess the following electrical output specifications: waveforms, output modes, maximum output voltage, maximum output current, pulse duration, frequency, net charge per pulse, maximum phase charge at 500 ohms, maximum current density, maximum average current, and maximum average power density.
( 2 ) Patient-contacting components of the device must be demonstrated to be biocompatible.
( 3 ) Performance testing must demonstrate the electrical, thermal, and mechanical safety along with electromagnetic compatibility (EMC) of the device in the intended use environment.
( 4 ) Software verification, validation, and hazard analysis must be performed.
( 5 ) Physician and patient labeling must include: ( i ) Summaries of electrical stimulation parameters;
( ii ) Instructions on how to correctly use and maintain the device;
( iii ) Instructions and explanations of all user-interface components;
( iv ) Information related to electromagnetic compatibility classification; and
( v ) Instructions on how to clean the device.
[82 FR 60116, Dec. 19, 2017]